Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Hypoxia × Magnetic Resonance Spectroscopy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 51 Carcinoma, Non-Small-Cell Lung 31 Lung Neoplasms 26 Breast Neoplasms 26 Glioblastoma 22 Glioma 18 Multiple Myeloma 16 Pancreatic Neoplasms 15 Lymphoma 15 Carcinoma, Renal Cell 15 Lymphoma, Large B-Cell, Diffuse 14 Urinary Bladder Neoplasms 13 Sarcoma 13 Brain Neoplasms 13 Squamous Cell Carcinoma of Head and Neck 11 Neoplasm Metastasis 10 Oropharyngeal Neoplasms 9 Neuroblastoma 9 Melanoma 9 Lymphoma, Non-Hodgkin 9 Lymphoma, Follicular 9 Ependymoma 9 Central Nervous System Neoplasms 9 Astrocytoma 9 Ovarian Neoplasms 8 Mouth Neoplasms 8 Medulloblastoma 8 Wilms Tumor 7 Triple Negative Breast Neoplasms 7 Rhabdoid Tumor 7

Interventions

Injections 2 3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol 2 pimonidazole 1 Nitroglycerin 1 Magnetic Resonance Spectroscopy 1 Hydroxychloroquine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02233387 2019-03-08

HX4-cervix

Maastricht Radiation Oncology

Phase 2 Terminated

Hypoxia, Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡